Lymphoprep™

Reference:
Brand

Product type

Datasheet of Lymphoprep™

About Lymphoprep™

• Lymphoprep™ is a ready-made, sterile and endotoxin-tested density gradient medium used to isolate mononuclear cells issued from cord blood, peripheral blood and bone marrow based on their cell density.
• Granulocytes and erythrocytes sediment through the Lymphoprep™ layer during centrifugation because they have a higher density than mononuclear cells.
• Lymphoprep™ can be used for the preparation of pure lymphocyte suspensions for tissue typing, antilymphocyte sera and immunological research.
• The use of Lymphoprep™ has been proven to be quick, simple, reliable, and has good outcomes with blood samples from most regular individuals and patients.

Product nameLymphoprep™
Delivery conditionRoom temperature
Delivery lead time in business days• Europe: 1-2 days
• USA& Canada: 2-3 days
• Rest of the World: 3-7 days
Storage conditionLymphoprep™ should be stored at room temperature.
It should be kept sterile and protected from light. Under these conditions Lymphoprep™ can be used for up to 3 years.
Prolonged exposure to direct sunlight leads to release of iodine from the sodium diatrizoate molecule. This effect is negligible when working with this solution on a day to day basis.
BrandAxis-shield
ApplicationsCell Isolation
CompositionThe solution contains sodium diatrizoate and polysaccharide in the following concentrations:
Sodium Diatrizoate 9.1% (w/v)
Polysaccharide 5.7% (w/v)
Principle of the separation procedurePrior to Lymphoprep, the most common technique for separating leucocytes is to mix blood with a compound which aggregates the erythrocytes, thereby increasing their sedimentation rate. The sedimentation of leucocytes is only slightly affected and can be collected from the upper part of the tube when the erythrocytes have settled.
Using a mixture of sodium metrizoate and polysaccharide – initial version of Lymphoprep™ - Bøyum (1968) developed a one-step centrifugal technique for isolation of lymphocytes. Thorsby and Bratlie (1970) used this technique with only slight modifications in the preparation of pure lymphocyte suspension for cytotoxicity tests and lymphocyte cultures. As emphasized also by other authors, Harris and Ukayiofo (1969), Ting and Morris (1971), Lymphoprep™ is a reliable, simple and quick method suitable for the preparation of lymphocyte preparations from cadaver blood, and from anticoagulated blood stored at room temperature for up to 6 hours.
Advantages

Lymphoprep™ vs Ficoll-Paque & Histopaque 1077


• Low endoxin
• Less expensive
• Lymphoprep™ is the only product of its kind produced under GMP conditions permitting reinjection of cells to patients
• Can be a good substitute for Ficoll-Paque™ with no further change of the existing protocols
Mononuclear cell separationhttps://www.proteogenix-products.com/documents/images/axis-shield/Separation-lymphoprep.png
ApplicationsCell Isolation
Alternatives

Lymphoprep™ can be a good substitution to:


Ficoll®
Ficoll-Paque
Histopaque
Buffy booster
Cell separation media
Related ProductsOptiPrep: The ideal density gradient medium
Lymphoprep™ Tube: Isolation of human mononuclear cells
Nycodenz AG: A universal density gradient medium
Polymorphprep: Isolation of human polymorphonuclear cells
Publications

Publication mentioning Lymphoprep™ include


1. King A, Birkby C, Loke YW. Early human decidual cells exhibit NK activity against K562 cell line but not against first trimester trophoblast. Cell Immunol 1989; 118:337–344.
2. Yeo C, Saunders N, Locca D, Flett A, Preston M, Brookman P, Davy B, Mathur A, Agrawal S. Ficoll-Paque vs. Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations, Regen Med , 2009, vol. 4 (pg. 689-696)
3. Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura
4. Bone Marrow?Derived Stem Cells Can Differentiate into Retinal Cells in Injured Rat Retina. 5. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32(14):1736-174721148540
Clear

Contact us to order

+33 (0)3 90 20 54 70

Write us